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Matrix metalloproteinases (MMPs) were initially recognised for their extracellular matrix (ECM)-degrading capability during tissue
remodelling. Their importance was further highlighted by their role in metastasis. Clinical trials have since evaluated the potential of
MMP inhibitors as anticancer therapeutics, but without success. These initial studies point to the complex, multifunctional capacity of
MMPs in cancer as shown by their function, not only as strident mediators of advanced malignancies, but also as effectors of early
stage tumorigenesis. Research now shows that MMPs, and their tissue inhibitors, affect tumour initiation and growth through loss of
cell adhesion, evasion of apoptosis, and deregulation of cell division. The extracellular nature of the metalloproteinase axis situates it
as a master regulator of cell fate.
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The extracellular microenvironment is a dynamic entity that
dictates cell function and cell fate. While extensive research has
established the importance of intrinsic cellular signalling path-
ways, the extracellular microenvironment is just as critical for
governing cell fate and function. The extracellular microenviron-
ment provides regulatory signals that affect important processes
such as cell adhesion, differentiation, division, and apoptosis.
Disruption of these functions can lead to acquisition of
tumorigenic properties, such as loss of contact inhibition, aberrant
cell division, and evasion of apoptosis.
Matrix metalloproteinases (MMPs) are essential regulators of
the cell’s microenvironment, through their control of extracellular
proteolysis. Owing to their extracellular matrix (ECM)-degrading
ability, the importance of MMPs during cancer progression was
initially highlighted in the dissemination of cancer cells during
metastasis. Since the ECM is a physical barrier, prevention of
proteolytic breakdown by MMPs represented a key therapeutic
target during tumorigenesis and many pharmaceutical companies
became involved in developing MMP inhibitors as anticancer
therapeutics. The failure of many clinical trials, thus far under-
taken with broad-specificity inhibitors of MMPs, highlights the
complexity of MMP biology. New research into the roles of MMPs
reveals a much more fundamental involvement in normal cell
function and in the initiation and promotion of tumorigenesis
beyond merely cancer cell migration.
Matrix metalloproteinases represents a family of proteases that
can process virtually any component of the ECM (Vu and Werb,
2000; Egeblad and Werb, 2002; Puente et al, 2003). They are Ca
2þ-
and Zn
2þ-dependent proteases that are activated by the removal
of an amino-terminal propeptide domain. Activation of MMPs is
achieved either by autoproteolysis or processing by another MMP
or a serine protease. While there are currently over 24 human
MMPs and homologues from other species, MMPs were initially
classified as collagenases, gelatinases, stromelysins, and matrily-
sins, based on their ECM substrate specificity. Current nomen-
clature employs a sequential numerical system as the list of
substrates has grown and these are not restricted to ECM
components. Based on shared functional domains, MMPs can be
divided into eight groups, of which five are secreted and three are
membrane-bound (Egeblad and Werb, 2002). Additionally, other
classes of proteases that share the metalloproteinase domain with
MMPs have been identified as ADAMs (A Disintegrin And
Metalloproteinase) and ADAM-TSs (ADAM with thrombospondin
domain) (Primakoff and Myles, 2000). Currently there are over 33
members of the ADAM family, which are cell surface-associated,
and over 17 members in the ADAM-TS family, which are secreted
proteins (Tang, 2001). However, not all of these have demonstrated
metalloproteinase activity. While the ECM substrates of ADAMs
are few and limited, they can proteolytically process a diverse
group of cell surface proteins including ligands and their
receptors.
The proteolytic activity of MMPs is regulated by a number of
physiological inhibitors. The nonspecific MMP inhibitor a2-
macroglobulin tethers MMPs to scavenger receptors, which are
then irreversibly endocytosed. Specific inhibition is mediated by
the Tissue Inhibitors of MetalloProteinases (TIMPs) (Vu and
Werb, 2000; Egeblad and Werb, 2002). TIMP-1 through TIMP-4
are secreted inhibitors that selectively and reversibly bind MMPs
in a 1:1 stoichiometry. Specific TIMPs also inhibit specific
ADAMs. Small molecules that possess TIMP-like domains such
as the carboxy-terminal fragment of the procollagen C-terminal
proteinase enhancer protein and the NC1 domain of collagen type
IV can also inhibit MMPs. REversion-inducing Cysteine-rich
protein with Kazal motifs (RECK) have been identified as a
membrane-bound MMP inhibitor (Oh et al, 2001). With the Received 12 June 2003; revised 4 August 2003; accepted 8 August 2003
*Correspondence: Dr R Khokha; E-mail: rkhokha@uhnres.utoronto.ca.
British Journal of Cancer (2003) 89, 1817–1821
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.comstaggering number of MMPs and ADAMs, and the limited number
of TIMPs and RECK, one can appreciate that a tightly regulated
balance between proteases and their inhibitors must exist at any
developmental and physiological stage. A disruption in this
balance is observed in many pathological conditions such as
arthritis, pulmonary emphysema, cardiovascular diseases, and
cancer.
While it is established that MMPs degrade ECM proteins and
therefore allow for cell migration, MMPs can also affect cell
regulatory signals, directly or indirectly, within the extracellular
microenvironment that impact intracellular signalling. In this
review, we discuss how the proteolytic axis constituted by MMPs/
TIMPs/ADAMs influences the basic cellular processes that underlie
cancer development, namely cell dissociation, death, and division
– the three D’s of tumorigenesis.
CELL DISSOCIATION
Cell adhesion is key to cellular organisation within a tissue. In
addition to prescribing order to a group of cells, cell adhesion
imposes a physical restriction that inhibits cell division when in
contact with a neighbouring cell, a process known as contact
inhibition. A key feature of transformation is the loss of cell
contact inhibition and organisation. Cell adhesion is accomplished
by cell–cell and cell–ECM contacts. Adherens junctions are
among the many multiprotein adhesion complexes that mediate
cell–cell contact. Upon cell contact, Ca
2þ-dependent homotypic
engagement of cadherins occurs, which allows for the docking of
other proteins such as catenins. This then acts as an actin
cytoskeleton nucleation point (Christofori, 2003). Cell–ECM
contact formation is mediated by the interaction of ECM
components with integrin molecules. Upon binding, the cytoplas-
mic tail of the integrin acts as a docking point for other signalling
molecules such as focal adhesion kinase (FAK) (Christofori, 2003).
Engagement of integrins also allows for the assembly of actin
cytoskeleton thus creating a link between the extracellular and
intracellular environments.
Matrix metalloproteinases can influence cell adhesion by
processing the extracellular components of cell–cell and cell–
ECM contacts. Cleavage of integrins is demonstrated in nonmeta-
static MCF-7 breast cancer cells. MMP-14-mediated processing of
pro-alpha(v) integrin subunit results in the maturation of
alpha(v)-beta(3) integrin facilitating invasion of these cells,
without altering its interaction with ECM components. It has been
proposed that the shift to invasive behaviour is due to increased
activation in FAK signaling, which is implicated in numerous
growth promoting pathways (Deryugina et al, 2002).
Cadherin-mediated cell–cell contacts are also subject to MMP
processing. Upon TIMP-1-downregulation, fibroblasts become
tumorigenic, at least in part, due to improper cell–cell and cell–
ECM contact formation, thereby circumventing contact-inhibited
growth (Ho et al, 2001). Upon treatment with MMP inhibitors,
these fibroblasts revert to a normal phenotype by restoring
adequate cell adhesion with increased localisation of b-catenin to
cell–cell contacts and increased FAK activation (Ho et al, 2001).
The loss of cell adhesion turns order into chaos. The shedding of
adhesion molecules contribute to altered cellular organisation and
architecture.
In addition to providing an initiating cue that can lead to
perturbations in survival signals, cell dissociation can lead to
changes in cellular differentiation pathways that further bestow
malignant phenotypes to normal cells (see Figure 1). A key
differentiation event during cancer progression is epithelial-to-
mesenchymal transition (EMT) (Birchmeier et al, 1996). During
EMT, epithelial cells progressively acquire characteristics that
transform them into a mesenchymal or fibroblast-like cell. This
can also lead to increased extracellular proteolytic activity that
facilitates migration (Birchmeier et al, 1996; Gilles and Thompson,
1996). The ability of MMPs to process cadherins contributes to the
initiation of EMT. MMP-3 or MMP-7 triggers EMT by cleavage of
E-cadherin (Noe et al, 2001). In these studies, the proteolytically
processed fragment of E-cadherin may disrupt cell–cell contacts
by interfering with the function of other full-length E-cadherin
molecules. Furthermore, using mammary epithelial cells, induction
of MMP-3 activity revealed a loss of desmoplakin and E-cadherin
at cell–cell contacts, with a subsequent decrease of b- and g-
catenins suggesting a disruption in adherens junction formation
(Lochter et al, 1997). In addition, an increase in the mesenchymal
marker vimentin was concomitant with a downregulation of
epithelial cytokeratins. Induction of MMP-3 also led to the
upregulation of the mesenchymal growth factor, keratinocyte
growth factor. Importantly, the molecular characteristics of EMT
triggered by MMP-3 expression were not reversed by either
removal of MMP-3 induction or addition of a broad-spectrum
MMP inhibitor (Lochter et al, 1997). Activation and induction of
other MMPs were also evident upon MMP-3 induction. These
observations suggest that MMP-3 activity may lead to an
irreversible cascade in the initiation of EMT.
The classically characterised role of MMPs in invasion and
metastasis is a further step in EMT. In addition to increased MMP
activity, MMPs become focused and localised during invasion.
MMP-2, MMP-9, and MMP-14 congregate at the leading edge of a
metastatic cell in order to facilitate confined and coordinated
breakdown of the ECM barrier (Nakahara et al, 1997). Focused
MMP activity may also promote migration in other ways. For
example, cleavage of CD44 by MMP-14 results in increased
motility in different cancer cell lines and mutation of the putative
MMP-14 cleavage site in CD44 inhibits migration (Kajita et al,
2001). Also, MMP-2 and MMP-14 cleavage of ECM components
such as laminin-5 reveal cryptic sites that act as chemotactic
factors that trigger invasion as well as activate signaling via the
EGF receptor (Giannelli et al, 1997; Schenk et al, 2003). The
acquisition of mesenchymal characteristics by epithelial cells
represents a key step in epithelial tumour progression. Matrix
metalloproteinases are important for the initiation and propaga-
tion of this differentiation programme.
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Figure 1 Perturbations in the extracellular proteolytic axis can lead to
dysregulation of cell dissociation, cell death, and cell division, the three D’s
of tumorigenesis. Shown are the molecules currently known to be
processed by metalloproteinases. These are linked to the loss of cell
adhesion underlying loss of cell contact inhibition and EMT, evasion of cell
death, and aberrant cell proliferation.
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Evasion of apoptosis permits cancer progression by allowing cell
survival despite unfavourable conditions. Through proteolysis of
various biologically active molecules, MMPs can positively or
negatively regulate apoptosis in a context-dependent manner.
MMP-7 releases membrane-bound Fas ligand, thereby triggering
apoptosis upon binding with the Fas receptor (Powell et al, 1999).
On the other hand, MMP-7 can inhibit apoptosis by proteolytic
generation of mature HB-EGF that promotes cell survival by
stimulating the ErbB4 tyrosine kinase receptor (Yu et al, 2002).
MMP-3 induces apoptosis when overexpressed in mammary
epithelial cells (Alexander et al, 1996), whereas MMP-11 over-
expression decreases spontaneous apoptosis in tumour xenografts
(Wu et al, 2001).
The role of MMPs in influencing apoptosis is further
complemented by studies on the role of TIMPs in apoptosis.
Generally, TIMP-1, TIMP-2, and TIMP-4 have been reported to
exert antiapoptotic effects, while the role of TIMP-3 in apoptosis
has proven complex. TIMP-1 inhibits mammary epithelial
apoptosis in transgenic mice (Alexander et al, 1996) and in human
breast cell lines (Li et al, 1999). TIMP-2 overexpression affords
B16F10 melanoma cells protection from apoptosis (Valente et al,
1998). Similarly, TIMP-4 can protect human breast cancer cells
from apoptosis (Jiang et al, 2001). Distinct from these TIMPs,
TIMP-3 can either enhance or suppress apoptosis. Adenoviral
infection studies have shown that high levels of TIMP-3 promote
apoptosis in several cell lines. However, the loss of TIMP-3
function also accelerates apoptosis in the involuting mammary
gland (Fata et al, 2001). It has been suggested that TIMP-3
overexpression stabilises death receptors sensitising the cell to
apoptosis (Smith et al, 1997) or activating the mitochondrial
apoptotic pathway in a FADD-dependent manner (Bond et al,
2002). The mechanisms by which individual TIMPs exert pro- or
antiapoptotic effects will become clearer once the relevant MMP or
ADAM substrates are identified. The relative levels, tissue
specificity, and spatiotemporal expression of MMPs, TIMPs, and
ADAMs will also influence the extracellular proteolytic axis. The
sum of these factors would then determine the commitment to
programmed cell death.
CELL DIVISION
The development of cancer requires an escape from the natural
breaks that keep cell division in check or oncogenic stimuli often
involving growth factors and their receptors, causing aberrant
cellular division. Studies using genetically modified mice have
revealed that generally upregulation of MMPs promote tumour
formation and growth, whereas loss of MMP expression or
increased expression of their inhibitors attenuates tumorigenesis.
For example, in mice with the APC
min mutation, genetic deletion of
MMP-7 slows the formation of intestinal adenomas (Wilson et al,
1997). Several chemical carcinogenesis models have been used to
study MMPs in the early events of tumorigenesis. MMP-1
transgenics show increased susceptibility to skin carcinogens
(D’Armiento et al, 1995), while MMP-9 null mice show decreased
tumour incidence in another skin carcinogenesis model (Coussens
et al, 2000). In the latter case, despite the deceased tumour
incidence, tumours that do form are high-grade and more
aggressive. Strikingly, transgenic mice that overexpress MMP-3,
MMP-7 or MMP-14 give rise to spontaneous mammary hyperpla-
sias and malignancies (Rudolph-Owen et al, 1998; Sternlicht et al,
1999; Ha et al, 2001) supporting a causal role for MMPs in cancer
development. Overall, trends between MMP expression and
tumorigenesis are not as straightforward as initially thought.
The role of MMPs in early neoplastic lesions can also be inferred
through studies of TIMPs, which should show opposing effects.
TIMP-1 expression was shown to slow chemical skin carcinogen-
esis (Buck et al, 1999) and when coexpressed in MMP-3
transgenics, inhibited the formation of spontaneous preneoplastic
and neoplastic lesions (Sternlicht et al, 1999). Moreover, TIMP-1
also effectively inhibits the formation of hepatocellular carcinoma
in mice with liver expression of SV40 T antigen (CRP-TAg).
Conversely, antisense expression of TIMP-1 enhances liver tumour
development (Martin et al, 1996) as well as augments mammary
epithelial proliferation (Fata et al, 1999). However, this phenom-
enon is not as simple as it first appears. Certain studies have
suggested that TIMPs may function independently of their MMP-
inhibitory activity. For example, TIMP-1 expression in APC
min
mice had no effect or augmented intestinal adenomas, although a
synthetic MMP inhibitor was effective in slowing tumour
formation (Heppner-Goss et al, 1998). Thus, despite tumour
attenuation by inhibition of general MMP activity, TIMP-1 did not
mimic this effect and, in fact, could promote tumour growth. Other
systems have also shown that TIMP gene delivery can stimulate
tumorigenesis (Guedez et al, 2001; Jiang et al, 2001). This
highlights the context-dependent effects of MMPs and TIMPs
during cancer development.
Key to the divergent and complex roles of MMPs and TIMPs on
cell proliferation is the discovery that metalloproteinases affect the
bioavailability of numerous growth factors and cytokines (Table 1).
For example, MMPs cleave growth factor binding proteins that
sequester and prevent growth factors from binding their receptors.
In CRP-TAg mice, TIMP-1 is able to inhibit neoplastic hepatocyte
Table 1 List of growth factor and cytokine substrates of MMPs and
ADAMs
Metalloproteinase
Growth factor/
cytokine targeted
(released from) Reference
MMP-1 IGF (IGFBP2) Vu and Werb (2000)
(IGFBP3) Vu and Werb (2000)
(IGFBP5) Vu and Werb (2000)
FGF (perlecan) Vu and Werb (2000)
TNF-a Gearing et al (1994)
MMP-2 IGF (IGFBP3) Vu and Werb (2000)
(IGFBP5) Vu and Werb (2000)
IL1-b Vu and Werb (2000)
TGF-b (decorin) Imai et al (1997)
(LAP) Yu and Stamenkovic (2000)
TNF-a Gearing et al (1994)
MMP-3 HB-EGF Egeblad and Werb (2002)
FGF (perlecan) Vu and Werb (2000)
IGF (IGFBP3) Vu and Werb (2000)
IL1-b Vu and Werb (2000)
TGF-b (decorin) Imai et al (1997)
TNF-a Gearing et al (1994)
MMP-7 TGF-b (decorin) Imai et al (1997)
TNF-a Gearing et al (1994)
Haro et al (2000)
HB-EGF Egeblad and Werb (2002)
MMP-9 IGF (IGFBP3) Vu and Werb (2000)
IL1-b Vu and Werb (2000)
TGF-b (LAP) Yu and Stamenkovic (2000)
TNF-a Gearing et al (1994)
VEGF (unknown) Bergers et al (2000)
sKitL Heissig et al (2002)
MMP-11 IGF (IGFBP-1) Manes et al (1997)
MMP-12 TNF-a Egeblad and Werb (2002)
MMP-14 TNF-a Egeblad and Werb (2002)
MMP-17 TNF-a English et al (2000)
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factor binding proteins (IGFBPs). This subsequently prevents the
circulating, abnormal levels of IGF-II from binding to the type I
IGF receptor and activating downstream proliferative signals
(Martin et al, 1999). Alternatively, MMPs can release ECM-bound
mitogens from the surrounding matrix such as TGF-b (Imai et al,
1997). TGF-b is further activated by cleavage of its binding protein,
latent activating protein (LAP), by MMP-2 and MMP-9 (Yu and
Stamenkovic 2000). In fact, MMP-2 deficiency phenocopies the
expression of a dominant-negative TGF-b receptor (Vu and Werb,
2001). Growth factor signalling can also be controlled by protease-
mediated receptor cleavage that sheds the ectodomains. For
example, MMP-2 can release fibroblast growth factor receptor-1
(FGFR-1; Levi et al, 1996). Other factors, including cytokines such
as tumour necrosis factor-alpha (TNF-a), also require cell-surface
shedding. Several MMPs have been shown to cleave TNF-a as well
as the TNF-a convertase (ADAM-17), which is the primary enzyme
that mediates this process (Black et al, 1997). Since upregulation of
growth factors is linked to tumorigenesis, understanding these
emerging biological connections that link the MMP/ADAM/TIMP
proteolytic axis to growth factor signalling is crucial in identifying
appropriate and effective therapeutics for cancer treatment.
PERSPECTIVE
From their initial discovery in tadpole tail resorption, MMPs have
catapulted into the spotlight. Initially known to be important in
metastatic dissemination, MMPs have emerged as regulators of
fundamental cellular processes. Their historic characterisation as
ECM remodelling enzymes is perhaps simply the edge of their
complex biological function and recent discoveries make it
necessary to reflect and reassess current strategies for MMP
inhibition in cancer. Along with the discovery of ADAMs that are
also inhibited by MMP inhibitors, the discovery of new MMP
substrates and mechanisms of action point to the adverse
interference of normal biological processes by broad-spectrum
inhibitors. Matrix metalloproteinases are no longer just mediators
of metastasis during late-stage malignancy, but affect tumour
initiation and growth through the loss of cell adhesion, evasion of
apoptosis, and deregulation of cell division. Even more perplexing
are the opposing roles of TIMPs on tumour growth and apoptosis
that may depend on their relative levels, the cellular context, and
the developmental programme. The challenge is to design
inhibitors that are highly targeted to specific proteolytic mechan-
isms that stifle different stages of tumour progression, while
preserving the normal tissue function. Continued research into
these mechanisms will prove both challenging and exciting.
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